A new market study, titled “Discover Global SAR Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.
Introduction
Increasing prevalence of soft tissue sarcoma, rising Research and Development activities on drugs and other therapies, are some of the growth factors boosting the growth of the market. Soft tissue sarcoma is a type of cancer that grows from tissues such as nerves, muscles, fats, blood vessels, and thick skin tissues.
There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, Kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. There are several drugs used for the treatment of soft tissue sarcomas such as sunitinib (Sutent), trabectedin (yondelis), sirolimus (Rapamune), bevacizumab (Avastin), doxorubicin (adriamycin), and others.
@Get Free Sample Report at https://www.wiseguyreports.com/sample-request/3792131-global-sar-market-2018-2025
WHAT ARE THE CRITICAL APPLICATION SEGMENTS OF SOFT TISSUE SARCOMA MARKET?
In Oct 2016, U.S. Food and Drug Administration approved Eli Lilly and Companys drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types of soft tissue carcinoma.
Clinical Trial Analysis:
Total Soft Tissue Sarcoma Studies: 1567
By Disease Type, the market is segmented into Local sarcoma, Regional sarcoma, and Metastatic sarcoma. By treatment type, the soft tissue sarcoma market is segmented into radiation therapy, targeted therapy, chemotherapy, anti-angiogenesis drugs, and Others.
Chemotherapy has the largest market share in the soft tissue sarcoma market. Further, by End-user, the market has been segmented into hospitals, oncology centers, and Others. Hospitals are dominating the global soft tissue sarcoma market during the forecast period due to increasing number of patients getting treatment at hospitals for soft tissue sarcoma and other relevant cancers.
Regional Insights:
Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America is leading the global soft tissue sarcoma market due to the high prevalence of cancer and soft tissue sarcoma. According to the American Cancer Society, there were more than 11,500 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. Asia-Pacific region is also growing due to rising awareness about increasing advanced treatments for cancer.
The major players of global Soft Tissue Sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Genentech), Johnson & Johnson Services, Teva Pharmaceutical Industries Ltd Celgene Corporation, and others.
Some recently approved drugs for the treatment of Soft Tissue Sarcoma are:
In June 2018, Taiwan Liposome Company, (TLC), a clinical-stage specialty pharmaceutical company declared the submission of an Investigational New Drug (IND) application with the U. S. FDA to initiate a Phase I/II, open-label, dose-escalation clinical trial of TLC178, a NanoX liposomal formulation of the anticancer drug vinorelbine, in pediatric rhabdomyosarcoma (a type of soft tissue sarcoma) patients.
The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.
Target Audience
Raw Material Suppliers/ Buyers
Product Suppliers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers
Why purchase the report?
Visualize the composition of the Global Soft Tissue Sarcoma market across each indication, regarding type and applications, highlighting the critical commercial assets and players.
Identify commercial opportunities in Global Soft Tissue Sarcoma by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the Global Soft Tissue Sarcoma market – level 4/5 segmentation
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
Product mapping in excel for the critical Global Soft Tissue Sarcoma products of all major market players
@Get Detailed Report at https://www.wiseguyreports.com/reports/3792131-global-sar-market-2018-2025
Table of Contents
Chapter 1. Methodology and Scope
1.1 Research methodology
1.2 Scope of the Report
Chapter 2. Executive Summary
Chapter 3. Industry Analysis
3.1 Market Drivers
3.2 Market Restraints
3.3 Porters Five Forces Analysis
3.3.1 Suppliers Power
3.3.2 Buyer Power
3.3.3 Industry Competition
3.3.4 Threat of new Entrant
3.3.5 Threat of Substitutes
Chapter 4. Global Soft Tissue Sarcoma Market Epidemiology
Chapter 5. Global Soft Tissue Sarcoma Market -Product Pipeline Analysis
Chapter 6. Global Soft Tissue Sarcoma Market -Clinical Trail Analysis
Chapter 7. Segmentation by Disease Type
7.1 Local sarcoma
7.2 Regional sarcoma
7.3 Metastatic sarcoma
Chapter 8. Segmentation by Treatment
8.1 Radiation Therapy
8.2 Chemotherapy
8.3 Targeted therapy
8.4 Anti-angiogenesis drugs
8.5 Other Treatments
Chapter 9. Segmentation by End-User
8.1 Hospitals
8.2 Oncology Centers
8.3 Others
Chapter 10. Geographical Analysis
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.1.4 Others
10.2 Europe
10.2.1 United Kingdom
10.2.2 Spain
10.2.3 Germany
10.2.4 France
10.2.5 Rest of Europe
10.3 Asia-Pacific
10.3.1 India
10.3.2 China
10.3.3 Australia
10.3.4 Japan
10.3.5 Rest of Asia-Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Rest of South America
10.5 Rest of the World
Chapter 11. Competitive Landscape
11.1 Market Share Analysis
11.2 Company Benchmarking
11.3 Key Strategies Adopted by Major Companies
Chapter 12 Company Profiles*
12.1 F. Hoffmann-La Roche Ltd.
12.2 GlaxoSmithKline Plc
12.3 Pfizer, Inc.
12.4 Johnson & Johnson Services, Inc.
12.5 Teva Pharmaceutical Industries Ltd.
12.6 Celgene Corporation
12.7 Bristol-Myers Squibb Company
12.8 Threshold Pharmaceuticals Inc.
12.9 Merck KGaA.
Chapter 12 Appendix
12.1 Sources
12.2 List of Tables
12.3 Expert Panel Validation
12.4 Disclaimer
12.5 Contact Us
*Note: Additional company profiles will be included on request
Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com